Your browser doesn't support javascript.
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Wang, Shuang; Peng, Yun; Wang, Rongjuan; Jiao, Shasha; Wang, Min; Huang, Weijin; Shan, Chao; Jiang, Wen; Li, Zepeng; Gu, Chunying; Chen, Ben; Hu, Xue; Yao, Yanfeng; Min, Juan; Zhang, Huajun; Chen, Ying; Gao, Ge; Tang, Peipei; Li, Gang; Wang, An; Wang, Lan; Zhang, Jinchao; Chen, Shuo; Gui, Xun; Yuan, Zhiming; Liu, Datao.
  • Wang S; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Peng Y; Beijing Kohnoor Science & Technology Co., Ltd, 102206, Beijing, China.
  • Wang R; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Jiao S; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Wang M; Beijing Kohnoor Science & Technology Co., Ltd, 102206, Beijing, China.
  • Huang W; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Shan C; Beijing Kohnoor Science & Technology Co., Ltd, 102206, Beijing, China.
  • Jiang W; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Li Z; Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, 100050, Beijing, China.
  • Gu C; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Chen B; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Hu X; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Yao Y; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Min J; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Zhang H; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Chen Y; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Gao G; Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Tang P; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Li G; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Wang A; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, 430071, Wuhan, Hubei, China.
  • Wang L; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Zhang J; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Chen S; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Gui X; Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, 100050, Beijing, China.
  • Yuan Z; Mabwell (Shanghai) Bioscience Co., Ltd, 201210, Shanghai, China.
  • Liu D; Ludwig Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK. ericshuochen@gmail.com.
Nat Commun ; 11(1): 5752, 2020 11 13.
Article in English | MEDLINE | ID: covidwho-926678
ABSTRACT
Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with FcγRIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Betacoronavirus / Antibodies, Monoclonal Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-19568-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / Betacoronavirus / Antibodies, Monoclonal Topics: Vaccines Limits: Animals / Female / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2020 Document Type: Article Affiliation country: S41467-020-19568-1